Gov Influence
Menu

Outside lobbying firm

Miller Strategies, LLC

Miller Strategies appears in Pfizer filings across both quarters. Health Issues recur alongside Medicare/Medicaid, tax, and budget categories, producing a compact view of pharmaceutical policy across care programs and fiscal questions.

Identity reviewed Sep 7, 2026 · Sources retrieved through Sep 4, 2026

Gov Influence analytical brief

Bottom-line assessment

Gov Influence assessmentModerate confidence

Miller Strategies, LLC’s reviewed filing pattern for Pfizer continued across both quarters, with Health Issues recurring.

HCR appears in 2 retained filings across Q1 and Q2; the firm’s profile contains 2 filings and 4 official issue codes.

Evidence and reasoning

Reasoning: The same approved registrant identity appears in canonical client filings in both quarters, and the same official issue code recurs across that span. Together those observations support a bounded assessment of a continuing disclosed filing pattern, while filing cadence and issue codes cannot establish priority, access, position, effectiveness, or policy impact.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Miller Strategies, LLC.

Other plausible interpretation

  • Quarterly LDA reporting cadence and the breadth of the HCR category may account for part of the recurrence; this two-quarter selection does not establish a longer-term pattern or work beyond the retained filings.

Method: firm-profile-assessment-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

These findings measure activity in retained disclosures; they do not rate access, effectiveness, or policy impact.

Supporting analysis

Key findings

Calculated from recordsHigh confidence

Miller Strategies, LLC appears in 2 retained filings for 1 reviewed client.

1 filing in 2026 Q1 and 1 filing in 2026 Q2; every client link resolves to its supporting canonical filings.

Evidence and reasoning

Reasoning: The calculation groups retained records by the approved LDA registrant ID, then counts distinct organization identities only after each client name passes that organization’s exact-name rule. It measures filing and client coverage in this collection, not total business, access, or influence.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Miller Strategies, LLC.

Method: firm-client-coverage-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

Calculated from recordsHigh confidence

Comparable outside-firm income was unchanged between Q1 and Q2.

2026 Q1 totals $150,000 and 2026 Q2 totals $150,000 from additive reported fields.

Evidence and reasoning

Reasoning: The calculation adds only reported and reported-zero outside-firm income fields within each quarter. Below-threshold, unreported, and absent values remain non-additive rather than becoming zero, and firm income is never combined with organization-reported expenses or interpreted as profit, access, effectiveness, or influence.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Miller Strategies, LLC.

Method: firm-income-comparison-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

Calculated from recordsHigh confidence

Miller Strategies, LLC’s retained filings contain 4 official issue codes.

HCR (Health Issues) appears in 2 filings across both quarters, the strongest recurring code pattern selected by filing frequency and deterministic code-order tie breaking.

Evidence and reasoning

Reasoning: Each official code is counted once per retained filing, while different codes may overlap. The result identifies breadth and recurrence in the source categories; broad LDA codes do not show a client’s position, the amount of work, importance, success, or influence.

Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Miller Strategies, LLC.

Method: firm-issue-breadth-v1

Editorial review: Gov Influence editorial review; Sep 8, 2026

Focused starting collection

Why this is in the initial collection

The firm was selected because its Pfizer records connect a recurring general health category to public-program and tax policy. The mix makes it possible to compare broad healthcare reporting with the fiscal categories that accompany it.

What this edition covers: This profile brings together 2 retained 2026-Q1 through 2026-Q2 filings for Pfizer, with issue codes, amount states, and source wording preserved.

Questions this page helps answer

  • How do health, Medicare, tax, and budget categories align in Miller Strategies' Pfizer filings?

Reviewed clients

Each relationship below comes from retained LDA filings that identify this firm's reviewed registrant ID and the client name admitted by that organization's exact-name rule.

Identified filing relationship

Pfizer

Filing basis: 2 retained canonical LDA filings identify registrant ID 401104313 and a client name admitted by Pfizer's reviewed exact-name rule.

This relationship does not establish a policy outcome or the nature of work beyond the filing text.

Inspect the 2 supporting filings

Issue activity

Official issue codes are broad. Plain-language themes appear only where an existing reviewed code mapping applies.

Official issue-code frequency in 2026-Q1 through 2026-Q2
Official code and labelReviewed themeFilingsActivity entries
HCR — Health IssuesHealthcare, Prescription Drugs and Medicare22
LBR — Labor Issues/Antitrust/WorkplaceNo reviewed plain-language mapping22
MMM — Medicare/MedicaidHealthcare, Prescription Drugs and Medicare22
TAX — Taxation/Internal Revenue CodeTaxes and Government Spending22

Reported income by quarter

These amounts are income reported by the firm for represented clients. They are not client in-house expenses, profit, political access, or influence.

Accessible income detail for 2026-Q1 through 2026-Q2
ClientQuarterAmount reported by firmStatus
Pfizer2026 Q1$150,000reported
Pfizer2026 Q2$150,000reported

The comparable numeric total is $300,000. Every retained income field in this profile is additive.

Filing timeline

This chronology shows retained quarterly filings, not every registration, contact, or amendment version.

  1. Pfizer · 1st Quarter - Report

    4 reported issue entries; $150,000.

  2. Pfizer · 2nd Quarter - Report

    4 reported issue entries; $150,000.

Detailed filings and source descriptions

Open each record to read the official source wording retained in the collection.

2026 1st Quarter (Jan 1 - Mar 31) · Pfizer · 4 issue entries
Client name as filed
PFIZER INC.
Registrant name as filed
MILLER STRATEGIES, LLC
Amount reported by firm
$150,000

MMM — Medicare/Medicaid

Medicare and healthcare policy issues as they relate to drug pricing.

Government entities listed: HOUSE OF REPRESENTATIVES, Treasury, Dept of

HCR — Health Issues

Oppose IRA, PREP Act and vaccine liability.

TAX — Taxation/Internal Revenue Code

General issues with tax reform and foreign tax issues.

LBR — Labor Issues/Antitrust/Workplace

Issues related to drug consolidation.

2026 2nd Quarter (Apr 1 - June 30) · Pfizer · 4 issue entries
Client name as filed
PFIZER INC.
Registrant name as filed
MILLER STRATEGIES, LLC
Amount reported by firm
$150,000

MMM — Medicare/Medicaid

Medicare and healthcare policy issues as they relate to drug pricing.

HCR — Health Issues

Issues related to 340B Program

Government entities listed: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

TAX — Taxation/Internal Revenue Code

General issues with tax reform and foreign tax issues.

LBR — Labor Issues/Antitrust/Workplace

Issues related to drug consolidation.

Government entities listed: Federal Trade Commission (FTC)

These links are shown because the reviewed filings identify a client or use an official code mapped to a reviewed issue. They do not imply coordination or policy impact.

Method and identity review

How this profile was prepared

Review aliases, identifier basis, dates, and calculation boundaries
Reviewed display name
Miller Strategies, LLC
Name shown in filings
MILLER STRATEGIES, LLC
Official registrant ID
401104313
Identity review
A stable LDA registrant ID, one exact reviewed source name, and an outside-income filing basis support publication without merging names.
Reviewed period
2026-Q1 through 2026-Q2
Review date
Sep 7, 2026

Only selected canonical filing versions are used after the organization exact-name and amendment rules. Income is grouped by client and reported quarter. Numeric totals exclude below-threshold, unreported, and absent values instead of treating them as zero.